Chemotherapy improves the survival of patients with advanced non-small cell lung cancer
(NSCLC), but tumor progression is often inevitable. Strategies are needed to improve the …

Abbreviations: CEA= carcinoembryonic antigen, CT= computed tomography, DDP=
cisplatin, DTX= docetaxel, EGFR= epidermal growth factor receptor, EGFR-TKI= epidermal …

Managing metastatic diseases involves defining the best strategy that is supposed to take
into account both efficacy and quality of life. To this end, clinicians use stop and go or …

Introduction and aims: A core outcome set (COS) is defined as an agreed standardised set
of outcomes that should be measured and reported, as a minimum, in all clinical trials in …

The search for new agents and for innovative strategies is warranted in the treatment of
advanced non small cell lung cancer (NSCLC) because the outcomes remain unsatisfactory …

Purpose Maintenance therapy is an effective treatment strategy for advanced non-small-cell
lung cancer (NSCLC). We aim to investigate whether age would affect the efficacy of …

Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival
is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 …

Maintenance therapy represents a new treatment paradigm for fit, untreated, advanced non-
small cell lung cancer patients when administering modern chemotherapeutic or targeted …

PFS (4.6 versus 4.3 months; HR 0.68, 95% CI, 0.57-0.80, P< 0.001), with the greatest benefit
observed in patients with adenocarcinoma histology (5.1 versus 4.4 months; HR 0.60, 95 …